Division of Recordati Industria Chimica & Farmaceutica SPA
Latest From Recordati Ilac
Alnylam's ALN-AS1 became the eighth announced therapy to receive a breakthrough designation in May 2017, breaking the previously monthly high of seven.
A PharmAsia News update shows Turkey working to get a handle on drug shortages, overuse of antibiotics and the scourge of counterfeit drugs.
A PharmAsia News update on Turkish biomedical regulatory policies, including reports that the government offered industry to keep discount rates secret and an 11.7% jump in exports in the first four months of 2014.
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing.
- Therapeutic Areas
- Gynecological, Urological
- Yeni Recordati Ilac ve Hammaddeleri AS
- Yeni Ilac Hammaddeleri San. ve Tic. AS
- Parent & Subsidiaries
- Recordati Industria Chimica & Farmaceutica SPA
- Senior Management
- Contact Info
Phone: 02 12 620 2850
Dogan Arasli Cad.
No. 219 34510
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.